Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.
about
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cellsRole of exosomes in immune regulationBoosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).Immunotherapy for melanoma.The role of quantitative PCR for the immune monitoring of cancer patients.Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patientsPeptide-based vaccines for cancer immunotherapy.Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysatePhenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.Supernatural T cells: genetic modification of T cells for cancer therapy.Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.Immunotherapy for melanoma: current status and perspectives.Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patientsMobilizing the low-avidity T cell repertoire to kill tumors.Cellular immunotherapy of cancer: an overview and future directions.Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.Targeting transforming growth factor beta to enhance cancer immunotherapy.Tumour regression induced by co-administration of MIP-3α and CpG in an experimental model of colon carcinoma.Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination.Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications.Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies.
P2860
Q24804892-B5B79A89-C94E-4598-99FA-60BDEF706034Q28248090-2BD1A51A-1D74-44D7-9CC9-B9D7D9D4C40DQ33768911-732DD461-337D-4F0A-BFAB-73611222C57EQ34496957-C79A5EFD-F8EB-4488-B151-49677E0C35F6Q34573035-A46069A4-4FF8-4396-81F9-9D5D4039515BQ34701413-7BB3CCC7-981D-42A9-8DB5-A604D8B21969Q35005930-6F8FE64F-6D3F-4BDF-A9CE-FF849B37B63FQ35021619-0828B311-3DA8-4AAA-BA5D-1D9AC77864C9Q35681508-4F6F0031-3250-4BA2-BB00-09D343FA6C79Q35768996-3AA9FF51-F45F-4879-800E-DBEAF546BC76Q35793849-46FD632C-82A9-4795-9C7B-49B657C27AF4Q35945339-91E3B632-02F7-457E-BF63-4E2CFE46BD7EQ36328805-1879BC3E-2AF8-41EA-B9E9-D352CFDC90DCQ36422849-D126F840-3729-452F-9463-FC0B869677C5Q36453216-EA2FA04B-E1A2-42E2-94C8-33D4C837F740Q36642308-EE3F8BC7-E668-46CA-A1D7-F893F7E8AD84Q36694874-E188F4E0-31A8-406E-B578-5F282FEDC421Q36891310-A4A8E689-CEF1-4BA1-B315-DBA51DFC6C24Q38673161-F3E8C90C-6D98-41FA-966B-2E67D7EE0341Q39732678-24BE93FF-FC58-4A8C-A4F6-99F6D108DD93Q40349910-46E1A0ED-C59A-4010-9257-3F211353D4DAQ40598793-80B5A74B-0EB8-4CF0-A0CD-CE45707B418EQ42747896-072BFAA6-F52B-4B72-B889-555AA8220F65Q44828889-C55A42E0-9C6D-4BC0-B7EC-C9BAAC4484E9Q45245826-1502D69B-A080-4D5B-B2B3-72629590B9D9Q46632481-0ED4C0D6-9BEE-4AFD-82BA-94157CC41355Q53303142-FD4F3589-7966-4B41-8ED6-06448A7F31A4Q53538542-8D86DC38-16B6-45F9-8654-7DAFB02807D4
P2860
Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@en
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@nl
type
label
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@en
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@nl
prefLabel
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@en
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@nl
P2093
P1476
Phase I trial of intravenous p ...... ents with metastatic melanoma.
@en
P2093
Kuniyoshi J
P356
10.1097/00002371-200101000-00008
P577
2001-01-01T00:00:00Z